Eli Lilly and Company (LLY)vsTalkspace Inc (TALK)
LLY
Eli Lilly and Company
$1,208.12
+7.13%
HEALTHCARE · Cap: $1.08T
TALK
Talkspace Inc
$5.19
-0.19%
HEALTHCARE · Cap: $869.41M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 30210% more annual revenue ($72.25B vs $238.37M). LLY leads profitability with a 35.0% profit margin vs 0.5%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
TALK
Hold41
out of 100
Grade: D
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Earnings expanding 181.1% YoY
Safe zone — low bankruptcy risk
18.2% revenue growth
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 34.6x book value
Smaller company, higher risk/reward
ROE of 1.0% — below average capital efficiency
0.5% margin — thin
Operating margin of 0.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : TALK
The strongest argument for TALK centers on EPS Growth, Altman Z-Score, Revenue Growth. Revenue growth of 18.2% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 42.9x leaves little room for execution misses.
Bear Case : TALK
The primary concerns for TALK are Market Cap, Return on Equity, Profit Margin. Thin 0.5% margins leave little buffer for downturns.
Key Dynamics to Monitor
TALK carries more volatility with a beta of 1.07 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 41/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Talkspace Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Talkspace Inc. is a virtual behavioral healthcare company. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?